Introduction: Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti-inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN. Methods: Metastatic breast tumor 4T1/luc cells and hepatocellular carcinoma HepG2 cells were selected as cell models. The effects of FFA in vitro on cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in 4T1/luc and HepG2 cells were investigated. The in vivo anti-tumor activity of MSNM@SFN co-administrating with FFA (MSNM@SFN +FFA) was evaluated in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model, respectively. Results: The results indicated that FFA could markedly decrease cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in both 4T1/luc and HepG2 cells. The enhanced anti-tumor activity of MSNM@SFN+FFA compared with that of MSNM@SFN was confirmed in the 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model in vivo, respectively. Discussion: MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) developed in this study is an alternative strategy for improving the therapeutic efficacy of MSNM@SFN via co-administration with NSAIDs.
Introduction
Tumor-associated inflammation is recognized as an emerging hallmark of cancer treatment. 1 Inflammation significantly contributes to tumor progression probably due to the stimulation of prostanoid production. 2 Clinical findings have shown that cyclooxygenase-2 (COX-2), a key isoenzyme for the production of prostaglandins (PGs), is overexpressed in many tumors. 3, 4 COX-2 is also a critical enzyme for synthesizing prostaglandin E2 (PGE2) in cancer cells and promoting PGE2 release. 5, 6 The released PGE2 in tumor microenvironments can activate existing cell dissemination to cell migration and invasion. 9 Thus, the COX-2/PGE2 axis can be selected as an anti-tumor target.
Non-steroidal anti-inflammatory drugs (NSAIDs) can be used as potential chemo-preventive agents against tumor cells due to their role in inhibiting the activity of cyclooxygenases (COXs). 10 Unfortunately, NSAIDs seem to exercise their anticancer adjuvant effects only through the inhibition of inducible COX2. 11 Therefore, the combination of NSAIDs with chemotherapeutic drugs may enhance the anti-tumor effects. 12, 13 The combination effects of NSAIDs with chemotherapeutic drugs were confirmed in many studies. 14 Flufenamic acid (FFA) is a non-steroidal anti-inflammatory drug (NSAID). The anti-inflammatory and analgesic effects of FFA were confirmed in the 1960s. 15 The anti-inflammatory mechanism of FFA was recognized mainly through the reduction in prostaglandin synthesis from arachidonic acid by inhibiting COXs. 16 Sorafenib (SFN), an orally administered multi-kinase inhibitor, was approved by the FDA for the clinical treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma. 17 The therapeutic effects of SFN in lung, breast, and other cancers were also investigated. 18, 19 SFN is a Biopharmaceutical Classification System (BCS) class II drug due to its poor solubility characteristics. Many strategies have been used to enhance the solubility of SFN, including SFN-loaded nanoparticles, 20, 21 solid dispersion, 22 liposome, 23 polymersomes, 24 and inclusion compounds, 25 among others.
In our previous research, we prepared SFN mesoporous silica nanomatrix (MSNM@SFN) to improve the solubility, dissolution, and bioavailability of SFN. 26 The enhanced anti-tumor activity of MSNM@SFN compared with SFN suspension was confirmed in MDA-MB-231 cells in vitro and in vivo. 26 Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti-inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN. Metastatic breast tumor 4T1/luc cells and hepatocellular carcinoma HepG2 cells were selected as cell models. The effects of FFA in vitro on cell migration, PGE2 secretion, and Aldo-keto reductases (AKR1C1 and AKR1C3, which catalyze NADPH-dependent reductions and are involved in biosynthesis, intermediary metabolism, and detoxification) levels in 4T1/luc and HepG2 cells were investigated. The in vivo anti-tumor activity of MSNM@SFN co-administrating with FFA (MSNM@SFN +FFA) was evaluated in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model, respectively. 
Materials and Methods

Cell Lines
Both the 4T1/luc cells (a murine metastatic breast tumor cell line) and HepG2 cells (a human hepatocellular carcinoma cell line) were obtained from the Cell Resource Center, Peking Union Medial College (Beijing, China). The cells were cultured according to conditions recommended by the American Type Culture Collection (ATCC).
Animals
Female BALB/c mice (18-20 g ) and female BALB/C nude mice (18-20 g ) were obtained from the Experimental Animal Center of Peking University Health Science Center. All care and handling of the animals were performed with the approval of the Experimental Animal Center of Peking University Health Science Center. Additionally, this study was performed following the National Institutes of Health guidelines for the use of experimental animals.
The Effect of FFA on 4T1/luc and HepG2 Cell Migration
The cell migration assay was performed via a wound healing assay according to our previous research. 27 were scraped with a sharp tip vertically by the marked lines to create a cell-free space. The floating cells were washed with PBS three times to remove them. The cells were then incubated with non-serum containing cell culture medium without or with FFA for another 24 h. The width of the cell-free space at 0 h and 24 h was imaged using an EVOS microorganism online observation instrument (EVOS xl, AMG, USA). The distance between the scratches was analyzed using ImageJ software. The migration rate was calculated via the following formula: migration rate (%) = (distance of scratch at 0 hdistance of scratch at 24 h) × 100%/distance of scratch at 0 h.
The Effect of FFA on PGE2 in 4T1/luc and HepG2 Cells
Cells were seeded onto 12-well plates at a density of 4 × 10 5 cells/well and routinely cultured in l mL of RPMI 1640 medium for 24 h. Then fresh medium containing 2% serum was added and the cells were incubated for an additional 6 h. Subsequently, the cells were pre-stimulated with TNF-α (20 ng/mL) for 2 h. Then FFA, MSNM@SFN, or MSNM@SFN+FFA was added, respectively. After 6 h, the media were collected and the PGE2 level was determined according to the manufacturer's protocols.
The Effect of FFA on AKR1C1 and AKR1C3 in 4T1/luc and HepG2 Cells 4T1/luc or HepG2 cells (1 × 10 5 cells/well) were seeded in confocal dishes (covered glass-bottom dishes) and incubated at 37°C for 24 h. The cells were then treated with FFA (20 μg/mL) at 37°C for 24 h. The cells were then washed three times with cold phosphate-buffered saline (PBS, pH 7.4). These cells were incubated with primary antibody (rabbit polyclonal to AKR1C1 and ab192785 and rabbit polyclonal to AKR1C3 and ab84327) and secondary antibodies (goat anti-rabbit IgG/Alexa Fluor 488, bs-0295G-AF488) according to the manufacturers' standard protocols. The nuclei were counterstained with Hoechst 33342. The cells were imaged with a confocal laser scanning microscope to observe the fluorescence signal distribution of AKR1C1 and AKR1C3 in the cells. For the control group, cells that were treated as previously described only without FFA were observed via confocal laser scanning microscopy.
The Anti-Tumor Activity of MSNM@SFN +FFA in a 4T1/luc Metastatic Tumor Model
The 4T1/luc cells (0.2 mL, 1 × 10 6 cells) were intravenously injected into the tail vein of female BALB/C mice.
Four days after 4T1/luc cell injection, the 4T1/luc tumorbearing mice were randomly divided into three groups (12 animals per group). We prepared SFN mesoporous silica nanomatrix (MSNM@SFN) at the ratio that SFN:Sylysia:HPMC: DSPE-PEG was 1:3:3:3 (w/w/w/w) as our previous research. 26 For preparation of MSNM@SFN+FFA, the MSNM@SFN was mixed with FFA at the ratio of MSNM@SFN:FFA 40:1 (w/w) or SFN:FFA 4:1(w/w). The dose of MSNM@SFN was 40 mg/kg of SFN similar with that in MDA-MB-231 tumor-bearing nude mice model. 26 And we selected the dose of FFA at 10 mg/kg according to previously reported references. 29, 30 Each group of mice was orally administered physiological saline as a control, MSNM@SFN (at a dose of 40 mg/kg SFN), or MSNM@SFN+FFA (at a dose of 40 mg/kg SFN and 10mg/kg FFA) every day for 14 days. For bioluminescent imaging, on days 6, 8, 10, 14, 17, and 20 after the 4T1/luc cell injection, a filter-sterilized solution (0.2 μm) of d-luciferin in PBS (15 mg/mL) was intraperitoneally injected (10 μL/g) 15 min before measuring the luminescence. The mice were then anesthetized with an initial dose of 5% isoflurane and a maintenance dose of 1.5% isoflurane. The mice were then imaged using the IVIS Spectrum (Xenogen, USA), and the bioluminescence signals were quantified by Living Image software 4.3.1. The survival time was calculated from the day of 4T1/luc cell injection (0 day) to the day of death. KaplanMeier survival curves were plotted for each group.
The Anti-Tumor Activity of MSNM@SFN +FFA HepG2 Tumor-Bearing Nude Mice Model
Male BALB/C nude mice were subcutaneously inoculated in the right armpits with 0.2 mL of the HepG2 cell suspension (5 × 10 6 cells/animal). Once the volume of tumors reached approximately 100-150 mm 3 on day 14, the mice were randomly assigned to four groups (five animals per group): group 1 was given physiological saline as a control, group 2 was given SFN suspension (40 mg/kg of SFN, oral gavage, once a day for 18 days), group 3 was given MSNM@SFN (40 mg/kg of SFN, oral gavage, once a day for 18 days), and group 4 was given MSNM@SFN +FFA (40 mg/kg of SFN, 10 mg/kg of FFA oral gavage, once a day for 18 days). Throughout the study, the mice were weighed regularly and their tumors were measured using calipers every other day. The tumor volumes were calculated using the following formula: V = length (cm) × width 2 (cm 2 ) × 0.5236. On day 34, all the mice were sacrificed, and the tumor tissues were removed. Tumor sections were used for TUNEL straining experiments. TUNEL staining was preformed according to the standard protocols provided by the manufacturers.
The Anti-Tumor Activity of MSNM@SFN +FFA on HepG2 Orthotopic Tumor-Bearing Nude Mice
Male BALB/C nude mice were surgically inoculated in the median liver lobe through a midline abdominal incision with 25 μL of the HepG2 cell suspension (5 × 10 6 cells/ animal). On day 14, the mice were randomly assigned to three groups (3 animals per group): group 1 was given physiological saline as a control, group 2 was given MSNM@SFN (40 mg/kg of SFN, oral gavage, once a day for 18 days), and group 3 was given MSNM@SFN +FFA (40 mg/kg of SFN, 10 mg/kg of FFA oral gavage, once a day for 18 days). On day 34, all of the animals were sacrificed and the livers excised. The tumors were measured using calipers. The tumor volumes were calculated using the following formula: V = length (cm) × width 
Statistical Analysis
All of the data are shown as the mean ± SD. The significance among groups was determined using a one-way analysis of variance (ANOVA), after which post hoc tests with the Bonferroni correction for comparisons between individual groups were performed. Statistical significance was p < 0.05.
Results
The effect of FFA on 4T1/luc or HepG2 cell migration was investigated by a wound healing assay. As shown in Figure 1 , the migration of the 4T1/luc cells was significantly inhibited by FFA depending on the concentration. Untreated 4T1/luc migrated into the denuded areas. The calculated migration rate was 60.6%. In the FFA treatment group, few migrated 4T1/luc cells were observed in the denuded areas ( Figure 1A ). The calculated migration rate was 18.0% at a concentration of 0.39 μg/mL (Table 1) . At the highest concentration (3.13 μg/ mL), the calculated migration rate was 5.7%. Compared with the untreated 4T1 group as a percentage of control (60.6%), the value of the inhibited ratio in the FFA 0.39 μg/mL and 3.13 μg/ mL treatment groups was 70.3% and 90.6%, respectively. Conversely, the amount of untreated HepG2 that migrated into the denuded areas was very low ( Figure 1B) . The calculated migration rate was only 20.9% (Table 1 ). In the FFA treatment group, the calculated migration rate was 14.8% at a concentration of 0.39 μg/mL and 4.6% at the highest concentration (3.13 μg/mL). Compared with the untreated HepG2 group as a percentage of control (20.9%), the value of the inhibited ratio in the FFA 0.39 μg/mL and 3.13 μg/mL treatment groups was 29.2% and 78.0%, respectively.
The Effect of FFA on the Secretion of PGE2 in the 4T1/luc and HepG2 Cells
The effect of FFA on the secretion of PGE2 in the 4T1/luc and HepG2 cells was evaluated. As indicated in Figure 2 , in the 4T1/luc and HepG2 cells, FFA significantly decreased the level of PGE2 secretion compared to that of control groups (p < 0.01).
The Effect of FFA on AKR1C1 and AKR1C3 in the 4T1/luc and HepG2 Cells
The effect of FFA on AKR1C1 and AKR1C3 in the 4T1/luc and HepG2 cells was investigated. As shown in Figures 3A  and 4A , the immunofluorescence analysis results indicated that the fluorescence of labeling AKR1C1 (green) was present in the 4T1/luc and HepG2 cells, showing that AKR1C1 was in the 4T1/luc and HepG2 cells. FFA significantly decreased the AKR1C1 levels in both the 4T1/luc and HepG2 cells compared with that of the control groups (p < 0.01) (Figures 3 and  4) . Similarly, AKR1C3 was in the HepG2 cells ( Figure 5A ) and FFA also significantly decreased the levels of ARK1C3 in HepG2 cells compared with the control groups (p < 0.01) ( Figure 5 ). We did not investigate the effect of FFA on AKR1C3 in the 4T1/luc because the murine AKR1C3 antibody was not been obtained.
The Anti-Tumor Activity of MSNM@SFN +FFA in a 4T1/luc Metastatic Tumor Model
As shown in Figure 6 , the fluorescence signal was observed in the control group mice on day 14 after 4T1/luc cell injection and gradually increased with time, demonstrating that 4T1/luc cells were localized in the mice lungs. In the MSNM@SFN treatment group, the fluorescence signal was also observed in the mice on day 14 after 4T1/luc cell injection and gradually increased with time, demonstrating that 4T1/luc cells were also localized in the mice lungs after MSNM@SFN administration. In contrast, the fluorescence signal was not observed in the MSNM@SFN+FFA treatment mice on days 14 and 17 after 4T1/luc cell injection, and only a slight fluorescence signal was observed on day 20, indicating that after MSNM@SFN+FFA treatment, the metastasized 4T1/luc cells in the mice lungs were minor. As shown in Figure 7 , the animals in the control group died on day 17 and all sacrificed on day 23 after 4T1/luc cell administration. The animals in the MSNM@SFN treatment group died on day 19 and 75% of the animals sacrificed on day 24. In the MSNM@SFN+FFA treatment group, the animals died on day 21 and only 33% of the animals sacrificed on day 24.
The Anti-Tumor Activity of MSNM@SFN +FFA HepG2 Tumor-Bearing Nude Mice Model
The in vivo anti-tumor activity of MSNM@SFN+FFA was also evaluated in HepG2 tumor-bearing nude mice. As shown in Figure 8 , tumor growth was significantly inhibited in the SFN treatment groups compared with the physiological saline treatment group (p < 0.05 or p< 0.01), but the effect varied. Anti-tumor activity demonstrated no significant difference between the MSNM@SFN and SFN suspension treatment groups. However, MSNM@SFN+FFA significantly inhibited the growth of HepG2 tumors compared with that of the MSNM@SFN and SFN suspension treatment groups (p < 0.01). The mean tumor sizes on day 34 after implantation in the MSNM@SFN+FFA, MSNM@SFN, and SFN suspension treatment groups were 107 ± 33, 240 ± 59, and 397 ± 240 mm 3 , respectively, compared with 1014 ± 332 mm 3 in Figure 1 In vitro cell migration in the 4T1/luc cells (A) and HepG2 cells (B) after treatment with FFA for 24 h. The red lines were scratches which were scraped with a sharp tip vertically by the marked lines to create a cell-free space. The scale bar is 100 μm. in Figure 9A , tumors from the MSNM@SFN+FFA treatment group exhibited more advanced cell apoptosis compared with the groups treated with physiological saline, SFN suspension, and MSNM@SFN treatment groups, respectively. The calculated results are shown in Figure 9B .
The in vivo anti-tumor activity of MSNM@SFN+FFA was also investigated in HepG2 orthotopic tumor-bearing nude mice. As shown in Figure 10 , the tumor sizes on day 34 after implantation in the MSNM@SFN+FFA and MSNM@SFN treatment groups were 34 and 46 ± 32 mm 3 , respectively, significantly lower than in the control group (289 ± 75 mm 3 ) (p < 0.01). Furthermore, in the MSNM@SFN+FFA treatment group, the tumors completely disappeared in 2 of 3 HepG2 orthotopic tumor-bearing nude mice on day 34 after HepG2 cell implantation.
Discussion
Many anti-cancer drugs are co-administered with SFN to improve their anti-tumor activity, such as combretastatin A4, 31 cisplatin, 32 doxorubicin, 33 paclitaxel, 34 trichostatin A, 35 cyclophosphamide, 1 and gemcitabine. 36 In addition, some natural products, such as usnic acid, 37 oleanolic acid, 38 betulinic acid, 39 capsaicin, 40 have also been reported for coadministration with SFN to enhance the anti-tumor effect. Considering the tumor-associated inflammation microenvironment, in the present study, FFA, a COX2 specific inhibitor, was co-administered with SFN. Unlike the previously reported SFN co-administered drug delivery systems, our SFN was MSNM@SFN, which was a solubilized system. We previously investigated and confirmed that there were no effects of FFA on the solubility, dissolution, and pharmacokinetic behavior of SFN in MSNM@SFN. 41 Considering our previous results of the anti-tumor activity of MSNM@SFN in MDA-MB-231 cells in vitro and in vivo, 26 in the present study, the antitumor activity of MSNM@SFN co-administrating with FFA was investigated in 4T1/luc and HepG2 cells in vivo.
Evidence suggests that the expression of COXs might be involved in breast cancer pathogenesis. 42 In breast cancer, COX-2 can be used as a biomarker to evaluate breast cancer risk in women with atypical hyperplasia. 43 The overexpression of COXs and PGE2 might stimulate breast tumor cell migration and metastasis. 44 Our results indicated that FFA could effectively inhibit 4T1/luc cell migration and decrease the level of PGE2 secretion in 4T1/luc cells, indicating the role of FFA in inhibiting COXs activity. Our in vivo anti-tumor activity results indicated the inhibiting effect and prolonging lifetime activity of MSNM@SFN+FFA in the 4T1/luc metastatic tumor model. The COX/PGE2 axis acts as a regulator of HIF-2α expression and activity to promote hepatocellular carcinoma (HCC) development and reduce SFN sensitivity by constitutively activating the TGF-α/EGFR pathway. Therefore, the potential of COX2 specific inhibitors for HCC treatment would enhance the response to SFN treatment. 45 It has been reported that the co-administration of SFN with celecoxib has synergistic anti-tumor activity in HCC. 46 The present study confirmed that FFA can effectively inhibit HepG2 cell migration and decrease the level of PGE2 secretion in HepG2 cells. The in vivo anti-tumor activity of the 47 Aldo-keto reductases, comprised of AKR1C1, AKR1C2, AKR1C3, and AKR1C4, can catalyze NADPH-dependent reductions and are involved in biosynthesis, intermediary metabolism, and detoxification. 48 The overexpression of AKR1C1 has been reported in many cancers, including breast cancer, non-small cell lung cancer, and bladder cancer. [49] [50] [51] AKR1C3 is also reported to be abundantly expressed in breast cancer, prostate cancer, and T cell acute lymphoblastic leukemia (T-ALL). [52] [53] [54] Controlling AKR1C activity using its inhibitors may lead to favorable therapeutic outcomes. 55 FFA is known to potently inhibit AKR1C3 in a non-selective manner as COX off-target effects. 56, 57 The To determine the effects of FFA on 4T1/luc or HepG cell proliferation, 4T1/luc or HepG2 cells were treated with FFA for 48 h. The proliferation of 4T1/luc or HepG2 cells was determined via SRB. The results indicated that the proliferative ratio of 4T1/luc or HepG cells treated with FFA (50 μg/mL) was 60.99 ± 2.72% or 51.47 ± 2.93%, respectively (Fig S1) .
FFA has slight to moderate toxicity (10-40% of cell death corresponding to 100 µM) in uterine cervical cancer cell lines. 58 The present study demonstrated that FFA had moderate anti-tumor activity (30-40% of cell death corresponding to 50 µg/mL) in 4T1/luc or HepG2 cells. FFA can also be used as a free radical scavenger and gap junction blocker in cancer cells. However, for normal cells in tumor surroundings, FFA has potential protective effect on normal cells in comparison to the role of FFA in cancerous cells. 59 The in vitro anti-tumor activity of MSNM@SFN+FFA on 4T1/luc and HepG2 cells was investigated. As shown in Table S1 , the IC 50 values of MSNM@SFN+FFA in 4T1/ luc and HepG2 cells were similar to that of MSNM@SFN and significantly lower than that of free SFN (p < 0.01), indicating that the anti-tumor activity of the MSNM@SFN +FFA in the 4T1/luc and HepG2 cells was significantly higher than that of the free SFN. 
Conclusion
In the present study, we co-administrated sorafenib mesoporous silica nanomatrix (MSNM@SFN) with flufenamic acid (FFA) to improve the anti-tumor activity of SFN. Our results indicated that the FFA can significantly decrease the cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in both 4T1/luc and HepG2 cells. The in vivo anti-tumor activity of MSNM@SFN+FFA was confirmed in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model. MSNM@SFN coadministrating with FFA is an alternative strategy for improving the therapeutic efficacy of MSNM@SFN via co-administration with NSAIDs. 
